4:20 PM
 | 
Aug 03, 2017
 |  BC Extra  |  Company News

Shire evaluating neurology pipeline

In its 2Q17 earnings report, Shire plc (LSE:SHP; NASDAQ:SHPG) said it will evaluate options for its neurology franchise, with the potential of spinning out the company’s core ADHD business into an independent public company. The company expects to complete its analysis by year end.

Shire’s ADHD sales comprised 17% of its product sales this quarter. The franchise revenues fell 3% to $635.4 million in 2Q17, primarily...

Read the full 314 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >